These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9619782)
21. In-vivo clearance study of vancomycin in rats. Nakamura T; Takano M; Yasuhara M; Inui K J Pharm Pharmacol; 1996 Nov; 48(11):1197-200. PubMed ID: 8961172 [TBL] [Abstract][Full Text] [Related]
22. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus. Chandrasekar PH; Levine DP; Price S; Rybak MJ J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959 [TBL] [Abstract][Full Text] [Related]
23. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Toyoguchi T; Takahashi S; Hosoya J; Nakagawa Y; Watanabe H Antimicrob Agents Chemother; 1997 Sep; 41(9):1985-90. PubMed ID: 9303398 [TBL] [Abstract][Full Text] [Related]
24. Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats. Sack K; Herhahn J; Marre R; Schulz E Infection; 1985; 13 Suppl 1():S156-60. PubMed ID: 3863794 [TBL] [Abstract][Full Text] [Related]
25. Modification of acquired immunity in mice by imipenem/cilastatin. Ortega E; de Pablo MA; Gallego AM; Gaforio JJ; Alvarez C; Ruiz-Bravo A; de Cienfuegos GA J Antimicrob Chemother; 1999 Oct; 44(4):561-4. PubMed ID: 10588322 [TBL] [Abstract][Full Text] [Related]
26. Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy. Zaballos M; Power M; Canal-Alonso MI; González-Nicolás MÁ; Vasquez-Jimenez W; Lozano-Lominchar P; Cabrerizo-Torrente P; Palencia-García N; Gago-Quiroga S; Ginel-Feito MD; Jiménez C; Lázaro A; González-Bayón L Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513824 [TBL] [Abstract][Full Text] [Related]
27. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes. Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314 [TBL] [Abstract][Full Text] [Related]
28. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Humanes B; Lazaro A; Camano S; Moreno-Gordaliza E; Lazaro JA; Blanco-Codesido M; Lara JM; Ortiz A; Gomez-Gomez MM; Martín-Vasallo P; Tejedor A Kidney Int; 2012 Sep; 82(6):652-63. PubMed ID: 22718191 [TBL] [Abstract][Full Text] [Related]
29. [A study on nephrotoxicity of arbekacin and vancomycin in rats]. Niizato T; Ohnishi M; Nishiyama S; Asaoka H; Saito A Jpn J Antibiot; 1994 Jun; 47(6):664-75. PubMed ID: 8072175 [TBL] [Abstract][Full Text] [Related]
30. Modification of natural immunity in mice by imipenem/cilastatin. Ortega E; de Pablo MA; Gallego AM; Alvarez C; Pancorbo PL; Ruiz-Bravo A; de Cienfuegos GA J Antibiot (Tokyo); 1997 Jun; 50(6):502-8. PubMed ID: 9268007 [TBL] [Abstract][Full Text] [Related]
31. The in vitro elution characteristics of vancomycin combined with imipenem-cilastatin in acrylic bone-cements: a pharmacokinetic study. Cerretani D; Giorgi G; Fornara P; Bocchi L; Neri L; Ceffa R; Ghisellini F; Ritter MA J Arthroplasty; 2002 Aug; 17(5):619-26. PubMed ID: 12168180 [TBL] [Abstract][Full Text] [Related]
32. Beneficial herb-drug interaction of rhein in Jinhongtang and Imipenem/Cilastatin mediated by organic anion transporters. Wu F; Zhao T; Zhang Y; Wang Y; Liao G; Zhang B; Wang C; Tian X; Feng L; Fang B; Huo X; Ma X J Ethnopharmacol; 2023 Aug; 312():116449. PubMed ID: 37023835 [TBL] [Abstract][Full Text] [Related]
33. The effects of experimental splenic autotransplantation and imipenem-cilastatin treatment in postsplenectomy Pseudomonas aeruginosa sepsis. Eskitürk A; Söyletir G; Peker O; Haklar G; Yalçin AS; Demirel M; Işgör A Res Exp Med (Berl); 1995; 195(3):163-9. PubMed ID: 8570911 [TBL] [Abstract][Full Text] [Related]
34. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation. Markewitz A; Hammer C; Pfeiffer M; Zahn S; Drechsel J; Reichenspurner H; Reichart B Transplantation; 1994 Mar; 57(6):865-70. PubMed ID: 8154033 [TBL] [Abstract][Full Text] [Related]
35. Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence. Tejedor A; Torres AM; Castilla M; Lazaro JA; de Lucas C; Caramelo C Curr Med Res Opin; 2007 Mar; 23(3):505-13. PubMed ID: 17355732 [TBL] [Abstract][Full Text] [Related]
36. Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin. Zhu Y; Huo X; Wang C; Meng Q; Liu Z; Sun H; Tan A; Ma X; Peng J; Liu K Asian J Pharm Sci; 2020 Mar; 15(2):252-263. PubMed ID: 32373203 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. Janmohamed RM; Leyland MJ; Kelly J; Farrell I J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419 [TBL] [Abstract][Full Text] [Related]
40. Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review. Shayan M; Elyasi S Expert Opin Drug Saf; 2020 Aug; 19(8):999-1010. PubMed ID: 32666842 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]